In Vitro Fertilization Treatment in Patients with Polycystic Ovaries
The most widely accepted clinical definition of polycystic ovary (PCO) syndrome is an association of hyperandrogenism with chronic anovulation in women without specific underlying diseases of the adrenal or pituitary glands. Usually, it presents with hypersecretion of luteinizing hormone and androgens but with normal or low serum concentrations of follicle-stimulating hormone (FSH), Infertility treatment in these patients is directed primarily toward induction or improvement of ovula-tion. Most of the patients will respond sufficiently to ovulation induction with clomiphene citrate (CC), however, the cumulative pregnancy rates with CC therapygenerally range between 40 and 50% (1) (2) (3) .
Gonadotropin prepartations are the next treatment of choice. The overall pregnancy rate for those patients who failed to conceive with CC, and were subsequently treated with gonadotropins, remained relatively low (around 30%) (4, 5) . Unfortunately, these cycles are associated with a high rate of multiple pregnancy (30%) and ovarian hyperstimulation syndrome.
Over the past 10 years, in vitro fertilization and embryo transfer (IVF-ET) have been offered successfully to patients who failed to conceive following ovulation induction or who have coexisting infertility factors. Beyond the therapeutic value, IVF treatment has opened new avenues of understanding the infertility of PCO patients. The ability to obtain follicular fluid and granulosa cells has opened new insights into the underlying pathophysiology.
A large body of evidence points toward an ovarian defect in patients with PCO. Over the years, we have learned that the initial steps in folliculogenesis, namely, recruitment and growth during the small antral stages, seem to be intact in PCO (6) . However, the next step of selection of dominant preovulatory follicles is lacking. The majority of patients with PCO have normal serum levels of FSH, which suggests that this defect may be due to biologially inactive FSH or a disorder of either local, intraovarian regulators or possibly a circulating inhibitor. The possibility of a biologically inactive FSH can probably be excluded since in vitro studies clearly showed an impaired response to exogenous FSH stimulation by PCO cells (7) compared with normal ovaries.
The main intraovarian regulators also do not differ between PCO and controls. Thus, no differences in cytokine concentrations in the follicular fluid were found between patients with PCO syndrome and normal subjects (8) . Jasper and Norman (1995) showed that there are no differences in the secretion of interleukin-1 (IL-1) and tumor necrosis factor (TNF) in PCO compared with normal granulosa ceils cultures (8) . Also, Eden et al. (9) did not find differences in follicular fluid concentrations of epidermal growth factor (EGF) and transforming growth factor e (TGF e) between PCO and normal ovaries.
The only difference found between PCO patients and those with normal ovaries was shown by Eden etal. (9) , who found a functional defect in the granuIosa cell aromatase complex in the patients with PCO. PCO cells clearly failed to demonstrate a normal capacity to synthesize progesterone in vitro. Furthermore, there is evidence of a functional defect of cytochrome P-450o17a, which catalyzes both 17e-hydroxilase and 17,20-1yase activities (10) . These in vitro studies highlight a local follicular disorder in PCO patients.
How are these findings reflected in clinical studies? Several years ago, we published our experience with IVF treatment for PCO patients (11) . This group of women was referred to IVF after failure to conceive, despite 10 cycles of confirmed ovulation with CC (6 cycles) and gonadotropins (4 cycles). Compared with a control group of normoovulatory women with tubal infertility who received similar induction protocols, the PCO patients responded with significantly higher ovarian steroid production and produced three times more eggs per oocyte collection than did the control group. Surprisingly, the fertilization and cleavage rates were significantly lower among the PCO patients, suggesting the possibility of oocyte dysmaturity as an explanation for the decreased fertility in these patients. Also, the pregnancy rates were not statistically different between the two groups, and this was attributed to the similar number of embryos available for transfer in both groups.
Based on these data and following the presumption that elevated circulating levels of luteinizing hormone (LH) in the follicular phase (12, 13) contribute to reduced fertilization and pregnancy rates in this group of patients, we performed a prospective study (14) . This study compared IVF results between PCO patients who received only gonadotropins for induction of ovulation and PCO patients pretreated with gonadotropins releasing hormone analogue (GnRH-a) before the gonadotropin administration. In the latter group, induction of ovulation was started only when the basal LH and FSH levels had decreased significantly, approaching the hypopituitary range. Paradoxically, the LH area under the curve did not differ between the two groups during the induction period. In the non GnRH-a group, a significant increase in LH levels was found only 1 day prior to human chorionic gonadotropin (hCG) administration. Neither follicular fluid steroid levels nor in vitro granulosal cell secretion of the steroid hormones differed between the two groups. The mean number of oocytes recovered and the fertilization rates were similar between the two groups. Furthermore, in both groups, up to 50% of the retrieved eggs were immature, thus providing a possible explanation for the low fertilization rates. These two studies were followed by several other studies performed by various authors who obtained similar results, i.e., higher numbers of oocytes with lower fertilization rates among PCO patient but similar pregnancy rates (15, 16) and pregnancy outcomes (17) . Based on these data, we postulate that PCO is mainly an ovarian disease. Further, we have also demonstrated that the major benefit of pituitary suppression with GnRH-a was related mainly to the flexibility in the induction interval (protocol) by prevention of early luteinization. The tendency for improved egg performances when GnRH-a is used, as suggested by Homburg et al. (t6), may be explained by the less strict criteria for hCG administration, with a possible prolongation of the induction period and'an increase in the percentage of mature eggs recruited. However, this may increase the risk of ovarian hyperstimulation syndrome (OHSS).
Prevention of OHSS remains the main challenge for physicians using gonadotropin treatment of PCO patients. Recently, Lanzone et al. suggested the use of GnRH-a instead of hCG in triggering follicular maturation and ovulation in patients at risk of developing OHSS (18) . Induction of ovulation by gonadatropins only, is a sine qua non condition for this protocol, and a judicious pretreatment program must take this possibility into consideration, especially in patients with a history of OHSS. Another possibility for preventing severe OHSS is to freeze all embryos and postpone ET for a "thawed" cycle.
The next most worrisome condition associated with PCO during in vivo and in vitro treatments is the high incidence of multiple pregnancies. Undoubtedly, IVF tends to be the only feasible treatment for reducing the incidence of multiple pregnancy. Recently, several studies have evidenced a reduction in the risk of high-rank multiple pregnancies, while offering patients an equal chance of pregnancy by limiting the number of fresh embryos transferred and freezing the remainder (19) .
What can we learn from these studies? (i) IVF-E-I-is a feasible treatment for women with PCO syndrome, supplying fairly good results regardless of any previous treatment attempts. (ii) Patients with PCO respond differently to ovarian hyperstimulation for IVF compared with patients with normal ovaries. (iii) An intrinsic "egg factor" is mainly responsible for the limited success of infertility treatment in these patients, thus contributing to our understanding of the condition. We learned that LH secretion during the proliferative phase is a result of the interaction between exogenous gonadotropins and the ovarian response and pituitary suppression before the induction period has a limited role in the final LH modulation.
We suggest oocyte collection and IVF with a limited number of replaced embryos or to postpone ET for a "thawed" cycle in patients with repeated or imminent QHSS after in vivo induction of ovulation with gonadotropins. A judicious embryo replacement policy may Ceduce the incidence of multiple pregnancies in this very high-risk group of patients.
INTRODUCTION
Polycystic ovarian syndrome (PCOS) is a fairly common clinical phenomenon among infertile patients. Classically these patients have been characterized by presenting with oligoamenorrhea and hyperandrogenism, as well as the usual associated infertility.
From the physiopathological point of view, the syndrome is characterized by chronically high levels of luteinizing hormone (LH) and androgens as welt as a peripheral resistance to insulin, which these patients compensate through their high levels of plasma insulin.
The endocrine anomalies presented by these patients make it difficult to obtain an adequate response to the usual ovarian stimulation protocols used in assisted reproduction techniques (ART). It seems that the high plasma LH levels have a deleterious effect on follicular maturation and compromise oocyte quality (9, 14) . It is accepted that these patients also have a greater tendency to miscarriage as a result of oocyte aging, which may come about as a consequence of the high levels of plasmatic LH (4). The literature on this topic shows that the majority of studies use different diagnostic criteria to catalog patients as affected by genuine PCOS, depending on whether clinical, ultrasound, or biochemical criteria are used (6) .
'In vitro fertilization is obviously not the first therapeutic option for PCO patients. Nevertheless, it can happen that a patient with these characteristics has failed after application of the usual therapeutic options for the syndrome or simply that she should undergo IVF because of an associated factor such as tubal pathology of male-factor infertility.
KEY POINTS
Knowing the tendency of these patients to show exaggerated responses when they are stimulated
